• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell Financial Year 2026 Interim Results

by chantal | Jan 29, 2026 | Investor Presentations, Investors, Presentations

Interim Results and Business Update

by chantal | Jan 29, 2026 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

by chantal | Jan 26, 2026 | Latest News, News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Notice of Interim Results and Investor Presentation

by chantal | Jan 22, 2026 | Latest News, News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

ESMO IO: Refining Standard of Care in Advanced Melanoma

by chantal | Dec 12, 2025 | Investor Presentations

« Older Entries
Next Entries »

Recent Posts

  • Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy